What is APH's health score?

AMPHENOL CORP /DE/ (APH) has a TradeApes health score of 73 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is APH's estimated fair value?

Based on our 5-year discounted cash flow model, AMPHENOL CORP /DE/'s estimated fair value is $62.79 per share, representing a -57.5% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is APH undervalued or overvalued?

Our model currently rates APH as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for APH... Refresh in a moment for the full analysis.

AMPHENOL CORP /DE/ (APH)

Technology Overvalued low healthy

$147.62

Updated: 2026-06-04

TradeApes Score

Financial Strength

85 Strong

Operating Trend

85 Strong

Relative Value

60 Healthy

Capital Allocation

55 Mixed

Risk

70 Healthy

Est. Fair Value $62.79

DCF Upside -57.5%

Sector Rank #554 of 7562

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− High P/E — 25–45×, growth premium already priced in

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.